Şunu aradınız:: anastrozole (Maltaca - İngilizce)

kura kombinata b’herceptin u anastrozole
combination treatment with herceptin and anastrozole

faslodex kien mill- anqas effettiv daqs anastrozole.
faslodex was at least as effective as anastrozole.

5 u anastrozole kien ta ’ 1. 01 (95% ci 0. 86 għal 1. 19).
the hazard ratio of fulvestrant to anastrozole for time to death was 1.01 (95% ci 0.86 to 1.19).

fil-prova pivitali (bo16216) herceptin u anastrozole ingħataw mill-ewwel ġurnata.
in the pivotal trial (bo16216) herceptin and anastrozole were administered from day 1.

l-għoti ta’ anastrozole fl-istess waqt ma deherx li jinfluwenza l-farmakokinetika ta’ trastuzumab.
the administration of concomitant anastrozole did not appear to influence the pharmacokinetics of trastuzumab.

ir- rata ta ’ rispons oġġettiv għal fulvestrant kienet ta ’ 19. 2% u 16. 5% għal anastrozole.
the objective response rate for fulvestrant was 19.2% compared with 16.5% for anastrozole.

meta wieħed jikkunsidra r- riżultati taż- żewġ studji meħudin f’ daqqa, il- marda ħadet medja ta ’ 166 jum biex tmur għall- agħar fil- pazjenti li rċevew 250 mg faslodex darba fix- xahar, meta mqabbel ma ’ 126 jum f’ dawk li ħadu anastrozole.
looking at the results of the two studies taken together, it took an average of 166 days for the disease to get worse in the patients receiving 250 mg faslodex once a month, compared with 126 days in those taking anastrozole.